Rush University Medical Center

Adhaere Pharmaceuticals, Inc.

The General Hospital Corporation

Other

149 Bio, LLC

Gb006, Inc.

Vineet Gupta

M Amin Arnaout

Jochen Reiser

Antonio J Barbosa

Anugraha Rajagopalan

Tristan Hays

Modified integrin polypeptides are provided. Methods of identifying binding agents that bind to a modified integrin polypeptide are also provided.

Reagents and assays using modified integrin domains

Compositions and methods are provided including a plurality of analyte detection agents, each analyte detection agent includes a labile tag operatively coupled to the analyte detection agent, each labile tag includes a signal that is different from each other labile tag and each analyte detection agent targeting a different analyte.

Sequential staining for multiplex analyses of tissues and cells

The following disclosure generally relates to methods of culturing podocytes in vitro. The cultures can be used for drug screening (such as medium or high throughput drug screening), and for studying molecular pathways involved in glomerular diseases. The disclosure also provides methods for analyzing the healthiness of podocytes in a cell culture. The disclosure also relates to diagnosis of kidney diseases.

Podocyte cultures and uses thereof

The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.

Compounds for modulating integrin CD11B/CD18

A method of treating inflammation, by administering an effective amount of a &#x3b2;2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a &#x3b2;2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a &#x3b2;2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a &#x3b2;2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a &#x3b2;2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating &#x3b2;2 integrins.

Compounds and methods for regulating integrins

The application describes small molecules capable of modulating activity of beta2 family of integrins, such as integrin CD11b/CD18 (also known as Mac-1, CR3 and &#x3b1;M&#x3b2;2). Such compounds may be used in certain embodiments for treating a disease or condition, such as inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, wound-healing, organ transplantation and cardiovascular disease, among others.

Compounds for modulating integrin CD11b/CD18

The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. For example, one such compound useful as an agonist of integrin CD11b/CD18 is the compound of Formula (I): Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.

Growing community of inventors

Pinecrest, FL, United States of America

Vineet Gupta